Trellis Bioscience, Inc. has amended its previous filing regarding its private offering, providing updated details on its efforts to raise capital through Series C interests. This amendment is significant as it highlights the company's ongoing commitment to securing funding in a competitive biotechnology landscape.

Background

Trellis Bioscience, Inc. is a biotechnology company incorporated in Delaware. The company has been active in the biotechnology sector, focusing on innovative solutions. Recent filings include a D/A on October 29, 2026, and several D forms on October 21, 2026, indicating ongoing fundraising efforts.

What the Filing Says

The filing states that the amendment is made under Rule 506(b), which provides a "safer harbor" for private offerings. It indicates that the total amount sold so far is $9,093,000, with the total offering amount remaining indefinite. The filing also notes that there are 16 investors involved in this offering.

Impact

This amendment may impact current and potential investors, as well as stakeholders in the biotechnology sector. The details provided in the filing suggest a structured approach to fundraising, which may attract more interest in the company's future projects.

What's Next

The filing does not say what happens next.

Company Details

Trellis Bioscience, Inc. is incorporated in Delaware and operates out of Redwood City, California. The company focuses on the biotechnology industry, with its business address listed as 702 Marshall Street, Suite 301, Redwood City, CA 94063. The company has been operational for over five years, indicating a level of stability in the competitive biotech sector.

Management Team

The filing identifies key executives at Trellis Bioscience, including Nora Mende, who serves as the Chief Financial Officer, and Larry Kauvar, the Chief Science Officer. Both executives are based at the company's Redwood City address, highlighting the centralization of leadership within the organization.

Offering Specifics

The amendment indicates that the offering is structured under Rule 506(b) of the SEC, which allows for a private offering without the need for extensive disclosures typically required for public offerings. The total amount sold to date is $9,093,000, with an indefinite total offering amount, suggesting flexibility in how much capital the company seeks to raise. Notably, there are no sales commissions or finders' fees associated with this offering, which may appeal to potential investors.

Investor Composition

The filing specifies that there are currently 16 investors involved in the Series C interests, all of whom are accredited investors. This detail underscores the company's focus on attracting experienced and financially capable investors, which could enhance the credibility and stability of the funding raised.

Use of Proceeds

While the filing does not provide specific details on how the proceeds from the offering will be utilized, it does indicate that no gross proceeds have been used to date. This could imply that the company is in the early stages of deploying the funds raised, which may be directed towards research and development or other operational needs.

Conclusion

The filing does not include any specific future plans or projections regarding the company's projects or potential expansions. Additionally, there is no mention of any upcoming milestones or product developments that might be anticipated as a result of this fundraising effort.